CDiddy,
I went back and crunched some numbers on my Samsung Biologics production capacity and had this to offer.
These are unverified numbers and only my estimations. If anyone knows differently please chime in. And I'm focusing on Samsung Biologics because they are the largest CMO that CytoDyn has worked with to have FDA certified production and quality for Leronlimab.
There are two CMO (contract manufacturing organization) that CytoDyn has under contract and are fully capable and certified by the FDA to produce Leronlimab - Samsung Biologics and AGC Biologics. Both have enormous capacity to produce. Samsung Biologics alone can currently produce up to 360,000 liters/year from their facilities. I think that works out to 120,000,000 vials per year (each vial 3ml)
Just based on Samsung's current theoretical manufacturing capacity:
My math....I hope my metric math is correct here....
So.... 1 Leronlimab dose = 3ml or .003L
360,000L / 3ml = 120,000,000 doses
-or-
360,000L / 0.003L = 120 million doses (wow...that's a lot)
120,000,000 doses / 4 doses = 30,000,000 patients
Average of 4 doses per patient treatment
And in recent news (Aug 17, 2020) - Samsung Biologics is adding another plant named "P4 Super Plant" that will add an additional 256,000L mAb production capacity bringing their total capacity to 620,000L per year. But the plant's operational date is expected to be 2022.
In 2022, Samsung Biologics can theoretically produce this much.
620,000L / 3ml = 206,666,666 million doses
-or-
360,000L / 0.003L = 206 million doses (wow...that's a lot)
206,666,666 doses / 4 doses = 51,666,666 patients
Average of 4 doses per patient treatment
But that would be pushing all their other customers out of the way during that entire year. Might be realistic to figure 25% of those figures could meet the world's needs.
I went back and crunched some numbers on my Samsung Biologics production capacity and had this to offer.
These are unverified numbers and only my estimations. If anyone knows differently please chime in. And I'm focusing on Samsung Biologics because they are the largest CMO that CytoDyn has worked with to have FDA certified production and quality for Leronlimab.
There are two CMO (contract manufacturing organization) that CytoDyn has under contract and are fully capable and certified by the FDA to produce Leronlimab - Samsung Biologics and AGC Biologics. Both have enormous capacity to produce. Samsung Biologics alone can currently produce up to 360,000 liters/year from their facilities. I think that works out to 120,000,000 vials per year (each vial 3ml)
Just based on Samsung's current theoretical manufacturing capacity:
My math....I hope my metric math is correct here....
So.... 1 Leronlimab dose = 3ml or .003L
360,000L / 3ml = 120,000,000 doses
-or-
360,000L / 0.003L = 120 million doses (wow...that's a lot)
120,000,000 doses / 4 doses = 30,000,000 patients
Average of 4 doses per patient treatment
And in recent news (Aug 17, 2020) - Samsung Biologics is adding another plant named "P4 Super Plant" that will add an additional 256,000L mAb production capacity bringing their total capacity to 620,000L per year. But the plant's operational date is expected to be 2022.
Quote:
https://bioprocessintl.com/bioprocess-insider...nstraints/
A fourth plant at its site in Incheon, South Korea will bring Samsung Biologics a total of 620,000 liters of biomanufacturing capacity – approximately 30% of the total global biologics CMO capacity
The contract development and manufacturing organization (CDMO) announced plans for what it calls the “P4 Super Plant” this week, explaining it plans to break ground at the site in Songdo within a year.
In 2022, Samsung Biologics can theoretically produce this much.
620,000L / 3ml = 206,666,666 million doses
-or-
360,000L / 0.003L = 206 million doses (wow...that's a lot)
206,666,666 doses / 4 doses = 51,666,666 patients
Average of 4 doses per patient treatment
But that would be pushing all their other customers out of the way during that entire year. Might be realistic to figure 25% of those figures could meet the world's needs.
3
